{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T12:37:14Z","timestamp":1782563834919,"version":"3.54.5"},"reference-count":55,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Department of Health and Human Services","award":["75A50119C00055"],"award-info":[{"award-number":["75A50119C00055"]}]},{"name":"the Department of Health and Human Services","award":["75A50119C00055"],"award-info":[{"award-number":["75A50119C00055"]}]},{"name":"the Department of Health and Human Services","award":["C06 RR012087"],"award-info":[{"award-number":["C06 RR012087"]}]},{"name":"the Department of Health and Human Services","award":["P51 OD011133"],"award-info":[{"award-number":["P51 OD011133"]}]},{"name":"Administration for Strategic Preparedness and Response","award":["75A50119C00055"],"award-info":[{"award-number":["75A50119C00055"]}]},{"name":"Administration for Strategic Preparedness and Response","award":["75A50119C00055"],"award-info":[{"award-number":["75A50119C00055"]}]},{"name":"Administration for Strategic Preparedness and Response","award":["C06 RR012087"],"award-info":[{"award-number":["C06 RR012087"]}]},{"name":"Administration for Strategic Preparedness and Response","award":["P51 OD011133"],"award-info":[{"award-number":["P51 OD011133"]}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["75A50119C00055"],"award-info":[{"award-number":["75A50119C00055"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["75A50119C00055"],"award-info":[{"award-number":["75A50119C00055"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["C06 RR012087"],"award-info":[{"award-number":["C06 RR012087"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["P51 OD011133"],"award-info":[{"award-number":["P51 OD011133"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Sabin Vaccine Institute","doi-asserted-by":"publisher","award":["75A50119C00055"],"award-info":[{"award-number":["75A50119C00055"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Sabin Vaccine Institute","doi-asserted-by":"publisher","award":["75A50119C00055"],"award-info":[{"award-number":["75A50119C00055"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Sabin Vaccine Institute","doi-asserted-by":"publisher","award":["C06 RR012087"],"award-info":[{"award-number":["C06 RR012087"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Sabin Vaccine Institute","doi-asserted-by":"publisher","award":["P51 OD011133"],"award-info":[{"award-number":["P51 OD011133"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Research Facilities Improvement Program","award":["75A50119C00055"],"award-info":[{"award-number":["75A50119C00055"]}]},{"name":"the Research Facilities Improvement Program","award":["75A50119C00055"],"award-info":[{"award-number":["75A50119C00055"]}]},{"name":"the Research Facilities Improvement Program","award":["C06 RR012087"],"award-info":[{"award-number":["C06 RR012087"]}]},{"name":"the Research Facilities Improvement Program","award":["P51 OD011133"],"award-info":[{"award-number":["P51 OD011133"]}]},{"DOI":"10.13039\/100016958","name":"the Southwest National Primate Research Center grant","doi-asserted-by":"publisher","award":["75A50119C00055"],"award-info":[{"award-number":["75A50119C00055"]}],"id":[{"id":"10.13039\/100016958","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016958","name":"the Southwest National Primate Research Center grant","doi-asserted-by":"publisher","award":["75A50119C00055"],"award-info":[{"award-number":["75A50119C00055"]}],"id":[{"id":"10.13039\/100016958","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016958","name":"the Southwest National Primate Research Center grant","doi-asserted-by":"publisher","award":["C06 RR012087"],"award-info":[{"award-number":["C06 RR012087"]}],"id":[{"id":"10.13039\/100016958","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016958","name":"the Southwest National Primate Research Center grant","doi-asserted-by":"publisher","award":["P51 OD011133"],"award-info":[{"award-number":["P51 OD011133"]}],"id":[{"id":"10.13039\/100016958","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Intramural Research Program of the Vaccine Research Center, NIAID, NIH","award":["75A50119C00055"],"award-info":[{"award-number":["75A50119C00055"]}]},{"name":"the Intramural Research Program of the Vaccine Research Center, NIAID, NIH","award":["75A50119C00055"],"award-info":[{"award-number":["75A50119C00055"]}]},{"name":"the Intramural Research Program of the Vaccine Research Center, NIAID, NIH","award":["C06 RR012087"],"award-info":[{"award-number":["C06 RR012087"]}]},{"name":"the Intramural Research Program of the Vaccine Research Center, NIAID, NIH","award":["P51 OD011133"],"award-info":[{"award-number":["P51 OD011133"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Marburg virus (MARV) is a virus of high human consequence with a case fatality rate of 24\u201388%. The global health and national security risks posed by Marburg virus disease (MVD) underscore the compelling need for a prophylactic vaccine, but no candidate has yet reached regulatory approval. Here, we evaluate a replication-defective chimpanzee adenovirus type 3 (ChAd3)-vectored MARV Angola glycoprotein (GP)-expressing vaccine against lethal MARV challenge in macaques. The ChAd3 platform has previously been reported to protect against the MARV-related viruses, Ebola virus (EBOV) and Sudan virus (SUDV), and MARV itself in macaques, with immunogenicity demonstrated in macaques and humans. In this study, we present data showing 100% protection against MARV Angola challenge (versus 0% control survival) and associated production of GP-specific IgGs generated by the ChAd3-MARV vaccine following a single dose of 1 \u00d7 1011 virus particles prepared in a new clinical formulation buffer designed to enhance product stability. These results are consistent with previously described data using the same vaccine in a different formulation and laboratory, demonstrating the reproducible and robust protective efficacy elicited by this promising vaccine for the prevention of MVD. Additionally, a qualified anti-GP MARV IgG ELISA was developed as a critical pre-requisite for clinical advancement and regulatory approval.<\/jats:p>","DOI":"10.3390\/vaccines10111935","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T02:31:27Z","timestamp":1668565887000},"page":"1935","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Single-Shot ChAd3-MARV Vaccine in Modified Formulation Buffer Shows 100% Protection of NHPs"],"prefix":"10.3390","volume":"10","author":[{"given":"Courtney L.","family":"Finch","sequence":"first","affiliation":[{"name":"Sabin Vaccine Institute, Washington, DC 20037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas H.","family":"King","sequence":"additional","affiliation":[{"name":"Sabin Vaccine Institute, Washington, DC 20037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6031-5360","authenticated-orcid":false,"given":"Kendra J.","family":"Alfson","sequence":"additional","affiliation":[{"name":"Texas Biomedical Research Institute, San Antonio, TX 78227, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie A.","family":"Albanese","sequence":"additional","affiliation":[{"name":"Battelle Biomedical Research Center, Madison County, OH 43162, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julianne N. P.","family":"Smith","sequence":"additional","affiliation":[{"name":"Battelle Biomedical Research Center, Madison County, OH 43162, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Smock","sequence":"additional","affiliation":[{"name":"Sabin Vaccine Institute, Washington, DC 20037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn","family":"Jakubik","sequence":"additional","affiliation":[{"name":"Sabin Vaccine Institute, Washington, DC 20037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yenny","family":"Goez-Gazi","sequence":"additional","affiliation":[{"name":"Texas Biomedical Research Institute, San Antonio, TX 78227, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Gazi","sequence":"additional","affiliation":[{"name":"Texas Biomedical Research Institute, San Antonio, TX 78227, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6253-2342","authenticated-orcid":false,"suffix":"III","given":"John W.","family":"Dutton","sequence":"additional","affiliation":[{"name":"Texas Biomedical Research Institute, San Antonio, TX 78227, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Clemmons","sequence":"additional","affiliation":[{"name":"Texas Biomedical Research Institute, San Antonio, TX 78227, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc E.","family":"Mattix","sequence":"additional","affiliation":[{"name":"Nonclinical Pathology Services, LLC, Medina, OH 44256, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Ricardo","family":"Carrion","sequence":"additional","affiliation":[{"name":"Texas Biomedical Research Institute, San Antonio, TX 78227, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Thomas","family":"Rudge","sequence":"additional","affiliation":[{"name":"Battelle Biomedical Research Center, Madison County, OH 43162, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Ridenour","sequence":"additional","affiliation":[{"name":"Battelle Biomedical Research Center, Madison County, OH 43162, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sovann F.","family":"Woodin","sequence":"additional","affiliation":[{"name":"Sabin Vaccine Institute, Washington, DC 20037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Hunegnaw","sequence":"additional","affiliation":[{"name":"Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy J.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Xu","sequence":"additional","affiliation":[{"name":"Clover Biopharmaceuticals, Boston, MA 02109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,15]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2022, January 08). Marburg Virus Disease. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/marburg-virus-disease."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ijid.2020.07.042","article-title":"Marburg virus disease: A summary for clinicians","volume":"99","author":"Kortepeter","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1056\/NEJMra1901594","article-title":"Ebola","volume":"382","author":"Feldmann","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_4","unstructured":"World Health Organization (2022, March 13). Regional Office for Africa West Africa\u2019s First-Ever Case of Marburg Virus Disease Confirmed in Guinea. Available online: https:\/\/www.afro.who.int\/news\/west-africas-first-ever-case-marburg-virus-disease-confirmed-guinea."},{"key":"ref_5","unstructured":"World Health Organization (2022, August 14). Marburg Virus\u2014Ghana. Available online: https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2022-DON402."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Towner, J.S., Pourrut, X., Albari\u00f1o, C.G., Nkogue, C.N., Bird, B.H., Grard, G., Ksiazek, T.G., Gonzalez, J.P., Nichol, S.T., and Leroy, E.M. (2007). Marburg virus infection detected in a common African bat. PLoS ONE, 2.","DOI":"10.1371\/journal.pone.0000764"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.3201\/eid2612.202108","article-title":"Shedding of marburg virus in naturally infected egyptian rousette bats, South Africa, 2017","volume":"26","author":"Storm","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Wolf, J., Jannat, R., Dubey, S., Troth, S., Onorato, M.T., Coller, B.A., Hanson, M.E., and Simon, J.K. (2021). Development of pandemic vaccines: ERVEBO case study. Vaccines, 9.","DOI":"10.3390\/vaccines9030190"},{"key":"ref_9","unstructured":"U.S. Food and Drug Administration (2022, January 08). First FDA-Approved Vaccine for the Prevention of Ebola Virus Disease, Marking a Critical Milestone in Public Health Preparedness and Response, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/first-fda-approved-vaccine-prevention-ebola-virus-disease-marking-critical-milestone-public-health."},{"key":"ref_10","unstructured":"European Medicines Agency (2022, January 08). First Vaccine to Protect Against Ebola. Available online: https:\/\/www.ema.europa.eu\/en\/news\/first-vaccine-protect-against-ebola."},{"key":"ref_11","unstructured":"Lui, A. (2021, December 09). Vaccines China Approves Domestic Ebola Vaccine Developed from Recent Outbreak. Available online: https:\/\/www.fiercepharma.com\/vaccines\/china-approves-self-developed-ebola-vaccine-from-2014-outbreak-virus-type."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41579-019-0187-4","article-title":"New filovirus disease classification and nomenclature","volume":"17","author":"Kuhn","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_13","unstructured":"European Medicines Agency (2021, December 08). New Vaccine for Prevention of Ebola Virus Disease Recommended for Approval in the European Union. Available online: https:\/\/www.ema.europa.eu\/en\/news\/new-vaccine-prevention-ebola-virus-disease-recommended-approval-european-union."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41541-020-00261-9","article-title":"Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate","volume":"5","author":"Roozendaal","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2015.01.041","article-title":"Structural Basis for Marburg Virus Neutralization by a Cross-Reactive Human Antibody","volume":"160","author":"Hashiguchi","year":"2015","journal-title":"Cell"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"8188","DOI":"10.1128\/JVI.00453-11","article-title":"The Cytoplasmic Domain of Marburg Virus GP Modulates Early Steps of Viral Infection","volume":"85","author":"Mittler","year":"2011","journal-title":"J. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(14)62385-0","article-title":"Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: A phase 1b, randomised, double-blind, placebo-controlled clinical trial","volume":"385","author":"Kibuuka","year":"2015","journal-title":"Lancet"},{"key":"ref_18","unstructured":"Albert, B. (2022, January 08). Sabin Vaccine Institute Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04723602?term=NCT04723602&draw=2&rank=1."},{"key":"ref_19","unstructured":"National Institute of Allergy and Infectious Diseases (2022, January 08). cAd3-Marburg Vaccine in Healthy Adults, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03475056."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.24272\/j.issn.2095-8137.2017.053","article-title":"Animal models for filovirus infections","volume":"39","author":"Siragam","year":"2018","journal-title":"Zool. Res."},{"key":"ref_21","first-page":"253","article-title":"Animal models of Ebolavirus infection","volume":"67","author":"Ragland","year":"2017","journal-title":"Comp. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.3389\/fimmu.2018.03071","article-title":"Protection against marburg virus using a recombinant VSV-vaccine depends on T and B cell activation","volume":"10","author":"Marzi","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"703986","DOI":"10.3389\/fimmu.2021.703986","article-title":"Recombinant Protein Filovirus Vaccines Protect Cynomolgus Macaques From Ebola, Sudan, and Marburg Viruses","volume":"12","author":"Lehrer","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"774026","DOI":"10.3389\/fimmu.2021.774026","article-title":"Single Dose of a VSV-Based Vaccine Rapidly Protects Macaques From Marburg Virus Disease","volume":"12","author":"Marzi","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Hunegnaw, R., Honko, A., Wang, L., Carr, D., Murray, T., Shi, W., Nguyen, L., Storm, N., Dulan, C.N.M., and Foulds, K.E. (Sci. Transl. Med., 2022). A Single-Shot ChAd3-MARV GP Vaccine Confers Rapid and Durable Protection Against Marburg Virus in non-human primates, Sci. Transl. Med., in press.","DOI":"10.1101\/2021.12.22.472410"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"10386","DOI":"10.1128\/JVI.00594-10","article-title":"Vector Choice Determines Immunogenicity and Potency of Genetic Vaccines against Angola Marburg Virus in Nonhuman Primates","volume":"84","author":"Geisbert","year":"2010","journal-title":"J. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s11262-017-1455-x","article-title":"Ebola and Marburg virus vaccines","volume":"53","author":"Reynolds","year":"2017","journal-title":"Virus Genes"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Callendret, B., Vellinga, J., Wunderlich, K., Rodriguez, A., Steigerwald, R., Dirmeier, U., Cheminay, C., Volkmann, A., Brasel, T., and Carrion, R. (2018). A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0196546"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1172\/JCI131958","article-title":"Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death","volume":"130","author":"Cross","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Matassov, D., Mire, C.E., Latham, T., Geisbert, J.B., Xu, R., Ota-Setlik, A., Agans, K.N., Kobs, D.J., Wendling, M.Q.S., and Burnaugh, A. (2018). Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge. J. Virol., 92.","DOI":"10.1128\/JVI.01190-17"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1473-3099(15)00362-X","article-title":"Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: A phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-bli","volume":"16","author":"Tapia","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1056\/NEJMoa1410863","article-title":"Chimpanzee Adenovirus Vector Ebola Vaccine","volume":"376","author":"Ledgerwood","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1093\/infdis\/jiy639","article-title":"Safety and immunogenicity of a heterologous prime-boost ebola virus vaccine regimen in healthy adults in the United Kingdom and Senegal","volume":"219","author":"Venkatraman","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S1473-3099(15)00486-7","article-title":"Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: A randomised, double-blind, placebo-controlled, dose-finding, phase 1\/2a study","volume":"16","author":"Audran","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.4049\/jimmunol.1202861","article-title":"Comparative Analysis of the Magnitude, Quality, Phenotype, and Protective Capacity of Simian Immunodeficiency Virus Gag-Specific CD8+ T Cells following Human-, Simian-, and Chimpanzee-Derived Recombinant Adenoviral Vector Immunization","volume":"190","author":"Quinn","year":"2013","journal-title":"J. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nm.3702","article-title":"Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge","volume":"20","author":"Stanley","year":"2014","journal-title":"Nat. Med."},{"key":"ref_37","unstructured":"Sabin Vaccine Institute (2022, January 12). GSK Grants Exclusive Technology License for Clinical-Stage Ebola Vaccines to Sabin Vaccine Institute. Available online: https:\/\/www.sabin.org\/updates\/pressreleases\/gsk-grants-exclusive-technology-license-clinical-stage-ebola-vaccines-sabin."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Alfson, K.J., Avena, L.E., Worwa, G., Carrion, R., and Griffiths, A. (2017). Development of a lethal intranasal exposure model of ebola virus in the cynomolgus macaque. Viruses, 9.","DOI":"10.3390\/v9110319"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"6773","DOI":"10.1128\/JVI.00649-15","article-title":"Particle-to-PFU Ratio of Ebola Virus Influences Disease Course and Survival in Cynomolgus Macaques","volume":"89","author":"Alfson","year":"2015","journal-title":"J. Virol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Alfson, K.J., Goez-Gazi, Y., Gazi, M., Staples, H., Mattix, M., Ticer, A., Klaffke, B., Stanfield, K., Escareno, P., and Keiser, P. (2021). Development of a well-characterized rhesus macaque model of ebola virus disease for support of product development. Microorganisms, 9.","DOI":"10.3390\/microorganisms9030489"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Alfson, K.J., Avena, L.E., Delgado, J., Beadles, M.W., Patterson, J.L., Carrion, R., and Griffiths, A. (2018). A Single Amino Acid Change in the Marburg Virus Glycoprotein Arises during Serial Cell Culture Passages and Attenuates the Virus in a Macaque Model of Disease. mSphere, 3.","DOI":"10.1128\/mSphere.00401-17"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Rudge, T.L., Sankovich, K.A., Niemuth, N.A., Anderson, M.S., Badorrek, C.S., Skomrock, N.D., Cirimotich, C.M., and Sabourin, C.L. (2019). Development, qualification, and validation of the Filovirus Animal Nonclinical Group anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay for human serum samples. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0215457"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Rudge, T.L., Machesky, N.J., Sankovich, K.A., Lemmon, E.E., Badorrek, C.S., Overman, R., Niemuth, N.A., and Anderson, M.S. (2022). Assays for the Evaluation of the Immune Response to Marburg and Ebola Sudan Vaccination&mdash;Filovirus Animal Nonclinical Group Anti-Marburg Virus Glycoprotein Immunoglobulin G Enzyme-Linked Immunosorbent Assay and a Pseudovirion Neutralization Assay. Vaccines, 10.","DOI":"10.3390\/vaccines10081211"},{"key":"ref_44","unstructured":"Jakubik, J., Holsberg, F., Shulenin, S., Smock, P., Albanese, K.A., Rudge, T., Xu, R., and Rustomjeee, R. (2021, January 18\u201322). Challenges in Production of High Purity Marburg Recombinant Glycoprotein for ELISA. Proceedings of the Immunogenicity & Bioassays Summit: Optimizing Bioassays for Biologics Conference, Washington, DC, USA."},{"key":"ref_45","unstructured":"(2011). Guide for Care and Use of Laboratory Animals, National Academies Press. [8th ed.]."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1242\/dmm.000471","article-title":"Disease modeling for Ebola and Marburg viruses","volume":"2","author":"Bente","year":"2009","journal-title":"DMM Dis. Model. Mech."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"9875","DOI":"10.1128\/JVI.01147-15","article-title":"Temporal Characterization of Marburg Virus Angola Infection following Aerosol Challenge in Rhesus Macaques","volume":"89","author":"Lin","year":"2015","journal-title":"J. Virol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Blair, P.W., Keshtkar-Jahromi, M., Psoter, K.J., Reisler, R.B., Warren, T.K., Johnston, S.C., Goff, A.J., Downey, L.G., Bavari, S., and Cardile, A.P. (2018). Virulence of marburg virus Angola compared to Mt. Elgon (Musoke) in macaques: A pooled survival analysis. Viruses, 10.","DOI":"10.3390\/v10110658"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Alfson, K.J., Goez-Gazi, Y., Gazi, M., Chou, Y.-L., Niemuth, N.A., Mattix, M.E., Staples, H.M., Klaffke, B., Rodriguez, G.F., and Bartley, C. (2022). Development of a Well-Characterized Cynomolgus Macaque Model of Marburg Virus Disease for Support of Vaccine and Therapy Development. Vaccines, 10.","DOI":"10.1101\/2022.05.04.490569"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Reynard, S., Gloaguen, E., Baillet, N., Madelain, V., Guedj, J., Raoul, H., de Lamballerie, X., Mullaert, J., and Baize, S. (2021). Early control of viral load by favipiravir promotes survival to ebola virus challenge and prevents cytokine storm in non-human primates. PLoS Negl. Trop. Dis., 15.","DOI":"10.1371\/journal.pntd.0009300"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"16142","DOI":"10.1038\/nmicrobiol.2016.142","article-title":"Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA","volume":"1","author":"Thi","year":"2016","journal-title":"Nat. Microbiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/nm.2447","article-title":"CD8 + cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates","volume":"17","author":"Sullivan","year":"2011","journal-title":"Nat. Med."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Cross, R.W., Longini, I.M., Becker, S., Bok, K., Boucher, D., Carroll, M.W., D\u00edaz, J.V., Dowling, W.E., Draghia-Akli, R., and Duworko, J.T. (2022). An introduction to the Marburg virus vaccine consortium, MARVAC. PLoS Pathog., 18.","DOI":"10.1371\/journal.ppat.1010805"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","article-title":"A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA","volume":"374","author":"Ewer","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Mire, C.E., Geisbert, J.B., Agans, K.N., Satterfield, B.A., Versteeg, K.M., Fritz, E.A., Feldmann, H., Hensley, L.E., and Geisbert, T.W. (2014). Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0094355"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/11\/1935\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:18:34Z","timestamp":1760145514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/11\/1935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,15]]},"references-count":55,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["vaccines10111935"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10111935","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,15]]}}}